Elevated serum levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 in chronic heart failure patients with left ventricular hypertrophy
Hiromichi Wada1, Tomohide Takaya1,2, Tatsuya Morimoto3, Yoichi Sunagawa4, Masatoshi Fujita4, Takeshi Kimura2, Yoshiko Fujita5, Yuko Sato5, Akira Shimatsu6, Tatsuya Sawamura5, Koji Hasegawa2.
- Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
- Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
World Congress of the International Society for Heart Research 2010 (Kyoto, Japan), 2010/05/16 (Poster).
Abstract
Background: Lectin-like oxidized low-density lipoprotein (oxLDL) receptor-1 (LOX-1) is now recognized as a multi-ligand receptor. Recently, we found that left ventricular (LV) expression of LOX-1 was markedly increased in the rat model of heart failure with LV hypertrophy (LVH). The extracellular domain of LOX-1 can be proteolytically cleaved and released into the blood stream in a soluble form (sLOX-1). However, the clinical significance of sLOX-1 in chronic heart failure (CHF) is unknown.
Methods and Results: We carried out a cross-sectional study including CHF patients with LVH (CHF-LVH) and apparently healthy subjects with normal LV dimensions and systolic function (control), and measured serum levels of sLOX-1. There were no significant differences in the age, body mass index, systolic and diastolic blood pressures, and heart rate between CHF-LVH and control groups. However, the LV end-diastolic dimension and LV mass index were significantly greater, and LV ejection fraction was significantly lower in the CHF-LVH than the control group. Interestingly, serum levels of sLOX-1 were significantly increased in the CHF-LVH compared to the control group.
Conclusion: These findings support the need for further investigations to assess the clinical utility and prognostic value of serum levels of sLOX-1 in patients with CHF.